GenMark Diagnostics Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GenMark Diagnostics stock.
View analyst ratings for GenMark Diagnostics or view top-rated stocks.

Wall Street analysts have given GenMark Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GenMark Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

GenMark Diagnostics is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for GenMark Diagnostics.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) issued its quarterly earnings results on Thursday, February, 25th. The medical equipment provider reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.04. GenMark Diagnostics had a negative net margin of 16.95% and a negative trailing twelve-month return on equity of 39.36%.
View GenMark Diagnostics' earnings history.

GenMark Diagnostics' stock was trading at $5.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GNMK stock has increased by 256.8% and is now trading at $19.34.
View which stocks have been most impacted by COVID-19.

GenMark Diagnostics updated its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $188-198 million, compared to the consensus revenue estimate of $182.47 million.

4 Wall Street analysts have issued twelve-month price targets for GenMark Diagnostics' stock. Their forecasts range from $15.00 to $24.00. On average, they anticipate GenMark Diagnostics' share price to reach $19.75 in the next twelve months. This suggests a possible upside of 2.1% from the stock's current price.
View analysts' price targets for GenMark Diagnostics or view top-rated stocks among Wall Street analysts.

4 employees have rated GenMark Diagnostics CEO Scott Mendel on Glassdoor.com. Scott Mendel has an approval rating of 75% among GenMark Diagnostics' employees.

Some companies that are related to GenMark Diagnostics include Integra LifeSciences (IART), Tandem Diabetes Care (TNDM), Nevro (NVRO), Inari Medical (NARI), ICU Medical (ICUI), iRhythm Technologies (IRTC), Glaukos (GKOS), ShockWave Medical (SWAV), NuVasive (NUVA), Cantel Medical (CMD), Merit Medical Systems (MMSI), AtriCure (ATRC), Axonics Modulation Technologies (AXNX), Pulmonx (LUNG) and Inovio Pharmaceuticals (INO).
View all of GNMK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Miragen Therapeutics (MGEN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO), CBL & Associates Properties (CBL) and Hallador Energy (HNRG).

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

GenMark Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.84%), Price T Rowe Associates Inc. MD (2.61%), William Blair Investment Management LLC (2.05%), Renaissance Technologies LLC (2.04%), Alyeska Investment Group L.P. (1.95%) and Alyeska Investment Group L.P. (1.95%). Company insiders that own GenMark Diagnostics stock include Alan Baer Maderazo, Brian Andrew Mitchell, Christine Shaw, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael John Harkins, Michael Kagnoff, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel and Tyler Jensen.
View institutional ownership trends for GenMark Diagnostics.

GNMK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, New York State Common Retirement Fund, Alyeska Investment Group L.P., Alyeska Investment Group L.P., Wells Fargo & Company MN, Nuveen Asset Management LLC, and Northern Trust Corp. Company insiders that have sold GenMark Diagnostics company stock in the last year include Alan Baer Maderazo, Brian Andrew Mitchell, Christine Shaw, Eric Stier, John Frederick Ek, Michael Gleeson, Michael John Harkins, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel, and Tyler Jensen.
View insider buying and selling activity for GenMark Diagnostics or view top insider-selling stocks.

GNMK stock was bought by a variety of institutional investors in the last quarter, including Samjo Capital LLC, Blue Water Life Science Advisors LLC, Paradigm Capital Management Inc. NY, William Blair Investment Management LLC, BlackRock Inc., First Trust Advisors LP, HighTower Advisors LLC, and Cowen Prime Services LLC. Company insiders that have bought GenMark Diagnostics stock in the last two years include Kevin C Oboyle, and Michael Kagnoff.
View insider buying and selling activity for GenMark Diagnostics or or view top insider-buying stocks.

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GNMK stock can currently be purchased for approximately $19.34.

GenMark Diagnostics has a market capitalization of $1.41 billion and generates $88.02 million in revenue each year. The medical equipment provider earns $-47,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

GenMark Diagnostics employs 618 workers across the globe.

The official website for GenMark Diagnostics is www.genmarkdx.com.

GenMark Diagnostics is headquartered at 5964 LA PLACE COURT, CARLSBAD CA, 92008.

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]